To this end, we chose napabucasin (BBI608), a small-molecule inhibitor of STAT3 [23], which has already been tested in a phase-III clinical trial for highly advanced, chemotherapy-refractory CRC [24], and which can be administered orally. The gene discussed is STAT3; the disease is colorectal carcinoma.